Clinical Trials Browser

Phase 3 × dostarlimab × Clear all

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT04655976 2025-09-26

COSTAR Lung

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06256588 2025-09-25

JADE

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT06762405 2025-02-18

PREDIR-NEOREC

Phase 3 Recruiting

GastrointestinalOther solid neoplasm

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms